A mi­cro­cap biotech salves old wounds with pos­i­tive PhII re­port on sta­tus epilep­ti­cus, but plen­ty of ques­tions re­main

The tiny mi­cro­cap biotech Mar­i­nus saw its shares $MRNS rock­et up af­ter post­ing a pos­i­tive sum­ma­ry of their mid-stage da­ta for IV ganax­olone in treat­ing drug-re­sis­tant cas­es of sta­tus epilep­ti­cus. And that at least tem­porar­i­ly helped heal some bad wounds left by the lat­est of sev­er­al set­backs ear­li­er in the year.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER